The FDA has granted Regenerative Medicine Advanced Therapy designation to NouvNeu001, a cell therapy for Parkinson’s disease.
NouvNeu001, developed by iRegene, is the first allogeneic cell therapy globally to hold both RMAT and Fast Track designations, according to a Jan. 19 company news release. The therapy is designed to replace lost dopaminergic neurons and restore dopamine production in patients with Parkinson’s disease, the second most common neurodegenerative disorder worldwide.
Phase 1 clinical trial data showed motor function improvements of up to 52.82% in the low-dose group and 54.67% in the ON-medication state at 12 months. Benefits were sustained through 15 months post-treatment.
The drugmaker plans to expand its pipeline of cell-based treatments targeting multiple system atrophy, early-onset Parkinson’s and retinal degeneration, with additional products in clinical or preclinical stages.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
